Cellares develops and manufactures cell therapies, focusing on biotechnology. The company operates as an Integrated Development and Manufacturing Organization (IDMO), which means it combines the development and manufacturing processes of cell therapies in one facility. This is different from traditional organizations that keep these processes separate. Cellares uses its proprietary "Smart Factory" technology, which includes an automated single-use cartridge system, to significantly enhance productivity, reduce costs, and lower failure rates in the manufacturing process. The company serves various clients, including those in preclinical, clinical, and commercial stages, and has partnerships with major pharmaceutical companies to automate the manufacturing of CAR-T cell therapies. Cellares aims to provide efficient and cost-effective manufacturing services, making it a competitive choice in the biotechnology sector.

EcoR1 Capital

Eclipse Ventures

Decheng Capital

Skyviews Life Science

Bristol-Myers Squibb

Koch Disruptive Technologies

Willett Advisors

DFJ Growth

Industrial & Manufacturing

Biotechnology

Cellares

Cellares, a Bridgewater-based leader in automated cell therapy manufacturing, on Monday announced it appointed Ossama Eissa, former executive at Novartis, Lonza Biologics, and Legend Biotech, as chief operating officer.

Cellares appoints former Novartis, Lonza and Legend Biopharma exec as COO

Cellares, a Bridgewater-based leader in automated cell therapy manufacturing, on Monday announced it appointed Ossama Eissa, former executive at Novartis, Lonza Biologics, and Legend Biotech, as chief operating officer.Eissa’s extensive experience will support the expansion of Cellares’ Smart Factory network in the United States, Europe, Japan and other international markets, addressing the challenges of scalability, cost, and quality that have long hindered patient access. Through these advancements, Cellares will work to ensure that life-saving treatments are accessible for oncology and autoimmune patients globally.This appointment strengthens the Cellares leadership team in a time of rapid global expansion of the company’s IDMO manufacturing services, in response to the growing global demand for cell therapy manufacturing capacity.Eissa brings more than 20 years of experience in pharmaceutical and biotech manufacturing.He formerly served as vice president and general manager at Legend Biotech, where he led the Raritan production site through the global launch of Carvykti, a CAR-T cell therapy.At Lonza Biologics, Eissa managed Global Strategic Projects, contributing significantly to the Cell and Gene Technologies Business Unit by boosting manufacturing efficiency and driving commercial scale-up. He also oversaw U.S. manufacturing operations at Novartis, scaling production and supporting regulatory approval for Kymriah, the first FDA-approved CAR-T cell therapy.“Joining Cellares is an opportunity to address one of the biggest challenges in healthcare today: making cell therapies accessible to all of those who need them,” Eissa said. “The mission aligns closely with my experience in scaling complex manufacturing systems to benefit patients directly. I’ve witnessed the profound impact these treatments have, and I’m committed to ensuring that we reach more patients, especially those facing cancer and autoimmune diseases, with the reliability and speed they deserve.”

Cellares Appoints Former Novartis, Lonza And Legend Biopharma Exec As Coo

Self-acclaimed integrated development and manufacturing organization (IDMO) Cellares has partnered with Sony Corporation, a technology firm focused on the field of flow cytometry, to integrate advanced flow cytometry-based cell analysis and sorting solutions into the Cellares Cell Shuttle platform.

Cellares and Sony partner to automate cell therapy manufacturing

Cellares, a leader in cell therapy manufacturing and an Integrated Development and Manufacturing Organization (IDMO), has appointed Justin McAnear as Chief Financial Officer (CFO) and Jonathan Butler as General Counsel and Corporate Secretary (GC).

Cellares Appoints CFO and General Counsel

PRINCETON, N.J. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, today announced a worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies in a transaction valued up to $380M in upfront and milestone payments. As part of the agreement, Cellares will optimize, automate, and tech-transfer select Bristol Myers Squibb CAR T cell therapies onto its automated and high-throughput manufacturing platform, the Cell Shuttle™. Cellares will dedicate multiple Cell Shuttle and Cell Q™ systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use. The Cell Shuttles and Cell Qs will be deployed in Cellares’ Smart Factories in the U.S., EU, and Japan. Manufacturing cell therapies is both operationally and technically complex

Bristol Myers Squibb And Cellares Announce A $380M Worldwide Capacity Reservation And Supply Agreement For The Manufacture Of Car T Cell Therapies To Bring The Promise Of Cell Therapy To More Patients, Faster

First cGMP Cell Q™ system for automated in-process and release QC of up to 6,000 cell therapy batches per year. (Photo: Business Wire)Cell Q™ integrates the vast majority of typical in-process and release QC assays for cell therapiesEach Cell Q™ automates the testing of up to 6,000 cell therapy batches per yearThe Cell Q™ includes a set of pre-qualified assays accelerating analytical transferCell Q™ uses a modular platform that can be expanded to incorporate new instruments providing the flexibility required to meet new IDMO client needsHigh-throughput automation of both manufacturing (Cell Shuttle™) and QC (Cell Q™) enables Cellares IDMO to offer up to 10x higher productivity while reducing batch prices by up to 50% compared with conventional CDMOsSOUTH SAN FRANCISCO, Calif., April 18, 2024--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, today unveiled Cell Q™, the first automated quality control (QC) workcell for cell therapy manufacturing. Cell Q™ addresses a critical challenge: the manual, labor-intensive, low-throughput, and expensive nature of cell therapy QC. Exclusive to Cellares’ industry-first IDMO Smart Factories, Cell Q™ will offer a substantial improvement in throughput, cost, and reproducibility compared to existing manual QC methods.As Cellares Cell Shuttles have addressed upstream bottlenecks in cell therapy manufacturing, Cell Q™ resolves the downstream QC capacity challenges. Cell Q™ is engineered to automate the vast majority of cell therapy QC assays for up to 6,000 batches per year. To accelerate analytical method transfer and shorten the time to clinical readout for new IDMO clients, Cell Q™ includes a pre-qualified set of the most common assays

Cellares Launches Cell Q, The World'S First Automated Cgmp Qc Workcell For Cell Therapies, To Resolve Manual Qc Processing Bottleneck And Extend Idmo Capabilities From Manufacturing Through Quality Control

First cGMP Cell Q™ system for automated in-process and release QC of up to 6,000 cell therapy batches per year. (Photo: Business Wire)First cGMP Cell Q™ system for automated in-process and release QC of up to 6,000 cell therapy batches per year. (Photo: Business Wire)SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, today unveiled Cell Q™, the first automated quality control (QC) workcell for cell therapy manufacturing. Cell Q™ addresses a critical challenge: the manual, labor-intensive, low-throughput, and expensive nature of cell therapy QC. Exclusive to Cellares’ industry-first IDMO Smart Factories, Cell Q™ will offer a substantial improvement in throughput, cost, and reproducibility compared to existing manual QC methods.As Cellares Cell Shuttles have addressed upstream bottlenecks in cell therapy manufacturing, Cell Q™ resolves the downstream QC capacity challenges. Cell Q™ is engineered to automate the vast majority of cell therapy QC assays for up to 6,000 batches per year

Cellares Launches Cell Q, The World’S First Automated Cgmp Qc Workcell For Cell Therapies, To Resolve Manual Qc Processing Bottleneck And Extend Idmo Capabilities From Manufacturing Through Quality Control

Cellares launches Cell Q automated cgmp QC workcell for cell therapies.

Cellares Launches Cell Q Automated cGMP QC Workcell for Cell Therapies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, a leader in the automation of cell therapy manufacturing and the world’s first Integrated Development and Manufacturing Organization (IDMO), today announced the addition of Christi Shaw to its Advisory Board. Ms. Shaw is a life sciences leader and advocate for patients with more than 30 years of pharmaceutical industry experience across a broad range of therapeutic areas. She formerly served as Chief Executive Officer of Kite, a Gilead Company, where she led a global team dedicated exclusively to the research, commercialization, and manufacturing of cell therapy. Under her leadership, Kite became a global leader in providing potentially curative cell therapies with multiple approved blood cancer indications in over 20 countries and led the company from treating a few hundred patients to thousands worldwide. Before Kite, she held senior executive positions at Lilly, Novartis, and Johnson  Johnson

Christi Shaw, Former Ceo Of Kite, A Gilead Company, Appointed To Cellares Advisory Board To Advance Cell Therapy Manufacturing

Cellares, a leader in the automation of cell therapy manufacturing and the world's first Integrated Development and Manufacturing Organization (IDMO), today announced the addition of Christi Shaw to its Advisory Board.

Christi Shaw, Former CEO of Kite, a Gilead Company, Appointed to Cellares Advisory Board to Advance Cell Therapy Manufacturing

Develops and manufactures cell therapies efficiently

Cellares

Develops and manufactures cell therapies efficiently

Cellares

Develops and manufactures cell therapies efficiently

About

Simplify's Take

What believers are saying

What critics are saying

What makes Cellares unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

Cellares is Hiring for 0 Jobs on Simplify!